Eisai Co., Ltd. (ESALF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Tokyo, Japan. The current CEO is Haruo Naito.
ESALF has IPO date of 2011-04-07, 11,067 full-time employees, listed on the Other OTC, a market capitalization of $8.46B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that develops and markets a diverse portfolio of prescription and over-the-counter products across multiple therapeutic areas. The company's key branded medications include Aricept for Alzheimer's disease and Lewy body dementia, Fycompa for epilepsy, Dayvigo for insomnia, and Lenvima for various cancers including thyroid, renal cell, and hepatocellular carcinoma. Eisai also markets Halaven for breast cancer and liposarcoma, Lyrica for pain management, Pariet for gastrointestinal disorders, and Humira for autoimmune diseases, alongside consumer health products such as vitamin supplements and designated quasi-drugs. The company serves the Japanese market as a leading player in both prescription pharmaceuticals and consumer health categories.
